Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARK trial of circulating microRNAs to guide immunotherapy strategy in PD-L1-high advanced non-small cell lung cancer
2022-502253-34-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Sep 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, paclitaxel, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Disease Control Rate. Planned start Sep 2023; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-502253-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502253-34-00.